



March 24, 2021

Case #: 600324

VIA ELECTRONIC MAIL

Paula H. Grahmann, Pharm.D.
Owner
Hallettsville Pharmacy, LLC
304 N. Texana Street
Hallettsville, TX 77964-2322

Dr. Grahmann:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Hallettsville Pharmacy, LLC, located at 304 N. Texana Street Hallettsville, TX 77964-2322, from November 5, 2018, to November 8, 2018, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Texas State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Dayna Martinez, Compliance Officer at (787) 729-8608, or by email at Dayna.Martinez@fda.hhs.gov.

Sincerely,

Digitally signed by John W. Diehl S4
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People, cn=John W. Diehl
S4,
0 9 2342 19200300 100 1 1-2000099727
Date: 2021.03.24 21:56:47 -05'00'

John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
1201 Main Street, Suite 7200
Dallas, Texas 75202
www.fda.gov